{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:06:46Z","timestamp":1792530406033,"version":"4.5.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Herzzentrum G\u00f6ttingen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Financial toxicity (FT) associated with cancer and its treatment has become increasingly important. This study investigated factors associated with the development of FT during radiation therapy (RT). SOCOFIN was the first longitudinal prospective study to systematically evaluate FT in the context of RT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Financial toxicity was measured with the Comprehensive Score for Financial Toxicity (COST-12) at RT initiation, completion, and at 3\u00a0months afterwards. Secondary endpoints included socioeconomic factors, health-related quality of life (EORTC QLQ-C30), depression (PHQ-9), coping mechanisms, and sense of coherence. The data were collected digitally; missing data were estimated using multiple imputation with chained equations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between July 2023 and June 2024, 230 patients were recruited. Analyses were performed on 170 records. During RT, FT did not increase; a\u00a0slight overall decrease was descriptively observed. Of seven tumor groups, the highest difference in FT at baseline was measured between prostate (median\u00a033) and pelvic cancer patients (median\u00a019), reaching statistical significance (Kruskal\u2013Wallis test,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u20090.01). Nonetheless, tumor entity was not found to be a\u00a0significant predictor of FT following RT in multivariate linear regression models. While factors associated with FT differed between timepoints, financial difficulties at baseline predicted the occurrence of FT most strongly (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&lt;\u200910\n                      <jats:sup>\u221213<\/jats:sup>\n                      ) and persistently.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Predictors of FT were predominantly socioeconomic, such as baseline financial difficulties, net income, employment stability, and sense of coherence, which superseded tumor- or treatment-specific variables. The findings of this study underscore the necessity of multifactorial, early screening before RT to mitigate FT among radiation oncology patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00066-025-02479-9","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:03:47Z","timestamp":1761224627000},"page":"330-348","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Longitudinal development and clinical predictors of financial toxicity among radiation oncology patients: final results of the SOCOFIN study"],"prefix":"10.1007","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3658-0404","authenticated-orcid":false,"given":"Anna Luisa","family":"Kreuser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Bendrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Asendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Rick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif Hendrik","family":"Dr\u00f6ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Leu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Guhlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Oelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Anna","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jann","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Braulke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Rieken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"El Shafie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"2479_CR1","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1093\/annonc\/mdz140","volume":"30","author":"J Witte","year":"2019","unstructured":"Witte\u00a0J, Mehlis\u00a0K, Surmann\u00a0B et\u00a0al (2019) Methods for measuring financial toxicity after cancer diagnosis and treatment: a\u00a0systematic review and its implications. Ann Oncol 30:1061\u20131070. https:\/\/doi.org\/10.1093\/annonc\/mdz140","journal-title":"Ann Oncol"},{"key":"2479_CR2","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1200\/JOP.2013.001322","volume":"10","author":"KM Fenn","year":"2014","unstructured":"Fenn\u00a0KM, Evans\u00a0SB, McCorkle\u00a0R et\u00a0al (2014) Impact of Financial Burden of Cancer on Survivors\u2019 Quality of Life. J\u00a0Oncol Pract 10:332\u2013338. https:\/\/doi.org\/10.1200\/JOP.2013.001322","journal-title":"J Oncol Pract"},{"key":"2479_CR3","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1200\/JCO.2015.64.6620","volume":"34","author":"SD Ramsey","year":"2016","unstructured":"Ramsey\u00a0SD, Bansal\u00a0A, Fedorenko\u00a0CR et\u00a0al (2016) Financial Insolvency as a\u00a0Risk Factor for Early Mortality Among Patients With Cancer. J\u00a0Clin Oncol 34:980\u2013986. https:\/\/doi.org\/10.1200\/JCO.2015.64.6620","journal-title":"J Clin Oncol"},{"key":"2479_CR4","doi-asserted-by":"publisher","first-page":"e408","DOI":"10.1016\/S2352-3026(15)00151-9","volume":"2","author":"SF Huntington","year":"2015","unstructured":"Huntington\u00a0SF, Weiss\u00a0BM, Vogl\u00a0DT et\u00a0al (2015) Financial toxicity in insured patients with multiple myeloma: a\u00a0cross-sectional pilot study. Lancet Haematol 2:e408\u2013e416. https:\/\/doi.org\/10.1016\/S2352-3026(15)00151-9","journal-title":"Lancet Haematol"},{"key":"2479_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ijrobp.2018.03.014","volume":"101","author":"JD Palmer","year":"2018","unstructured":"Palmer\u00a0JD, Patel\u00a0TT, Eldredge-Hindy\u00a0H et\u00a0al (2018) Patients Undergoing Radiation Therapy Are at Risk of Financial Toxicity: A\u00a0Patient-based Prospective Survey Study. Int J Radiat Oncol 101:299\u2013305. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.03.014","journal-title":"Int J Radiat Oncol"},{"key":"2479_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/11795549221147730","author":"M Rosi-Schumacher","year":"2023","unstructured":"Rosi-Schumacher\u00a0M, Patel\u00a0S, Phan\u00a0C, Goyal\u00a0N (2023) Understanding Financial Toxicity in Patients with Head and Neck Cancer: A\u00a0Systematic Review. Clin Med Insights Oncol. https:\/\/doi.org\/10.1177\/11795549221147730 (11795549221147730)","journal-title":"Clin Med Insights Oncol"},{"key":"2479_CR7","doi-asserted-by":"crossref","unstructured":"Mehlis K, Witte J, Surman B et\u00a0al (2020) The patient-level effect of the cost of Cancer care\u2014financial burden in German Cancer patients. Bmc Cancer","DOI":"10.1186\/s12885-020-07028-4"},{"key":"2479_CR8","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00761-021-00931-w","volume":"27","author":"SL Lueckmann","year":"2021","unstructured":"Lueckmann\u00a0SL, Kowalski\u00a0C, Schumann\u00a0N (2021) Finanzielle Toxizit\u00e4t einer Krebserkrankung: Aktuelles Verst\u00e4ndnis und Stand der internationalen und deutschen Forschung zu objektiven finanziellen Belastungen und subjektivem finanziellem Distress. Onkol 27:759\u2013765. https:\/\/doi.org\/10.1007\/s00761-021-00931-w","journal-title":"Onkol"},{"key":"2479_CR9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.13109\/zptm.2007.53.1.62","volume":"53","author":"S Tagay","year":"2007","unstructured":"Tagay\u00a0S, Senf\u00a0W, Sch\u00f6pper\u00a0N et\u00a0al (2007) Protektive Faktoren f\u00fcr Angst und Depression bei Schilddr\u00fcsenkarzinompatienten. Z\u00a0Psychosom Med Psychother 53:62\u201374. https:\/\/doi.org\/10.13109\/zptm.2007.53.1.62","journal-title":"Z Psychosom Med Psychother"},{"key":"2479_CR10","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s00066-022-01936-z","volume":"198","author":"A Fabian","year":"2022","unstructured":"Fabian\u00a0A, Domschikowski\u00a0J, Greiner\u00a0W et\u00a0al (2022) Financial toxicity in cancer patients treated with radiotherapy in Germany\u2014a cross-sectional study. Strahlenther Onkol 198:1053\u20131061. https:\/\/doi.org\/10.1007\/s00066-022-01936-z","journal-title":"Strahlenther Onkol"},{"key":"2479_CR11","doi-asserted-by":"publisher","first-page":"109604","DOI":"10.1016\/j.radonc.2023.109604","volume":"183","author":"A Fabian","year":"2023","unstructured":"Fabian\u00a0A, R\u00fchle\u00a0A, Domschikowski\u00a0J et\u00a0al (2023) Financial toxicity in cancer patients undergoing radiotherapy in a\u00a0universal health care system\u2014A prospective multicenter study of 1075 patients. Radiother Oncol 183:109604. https:\/\/doi.org\/10.1016\/j.radonc.2023.109604","journal-title":"Radiother Oncol"},{"key":"2479_CR12","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1186\/s12916-015-0433-1","volume":"13","author":"M Kimman","year":"2015","unstructured":"Kimman\u00a0M, Jan\u00a0S, Kimman\u00a0M et\u00a0al (2015) Catastrophic health expenditure and 12-month mortality associated with cancer in Southeast Asia: results from a\u00a0longitudinal study in eight countries. BMC Med 13:190. https:\/\/doi.org\/10.1186\/s12916-015-0433-1","journal-title":"BMC Med"},{"key":"2479_CR13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40271-016-0204-x","volume":"10","author":"LG Gordon","year":"2017","unstructured":"Gordon\u00a0LG, Merollini\u00a0KMD, Lowe\u00a0A, Chan\u00a0RJ (2017) A Systematic Review of Financial Toxicity Among Cancer Survivors: We Can\u2019t Pay the Co-Pay. Patient\u2014patient-centered Outcomes Res 10:295\u2013309. https:\/\/doi.org\/10.1007\/s40271-016-0204-x","journal-title":"Patient\u2014patient-centered Outcomes Res"},{"key":"2479_CR14","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1002\/cncr.28814","volume":"120","author":"JA De Souza","year":"2014","unstructured":"De Souza\u00a0JA, Yap\u00a0BJ, Hlubocky\u00a0FJ et\u00a0al (2014) The development of a\u00a0financial toxicity patient-reported outcome in cancer: The COST measure: Financial PRO Measure in Cancer. Cancer 120:3245\u20133253. https:\/\/doi.org\/10.1002\/cncr.28814","journal-title":"Cancer"},{"key":"2479_CR15","doi-asserted-by":"publisher","first-page":"6618","DOI":"10.1200\/jco.2015.33.15_suppl.6618","volume":"33","author":"JA De Souza","year":"2015","unstructured":"De Souza\u00a0JA, Wroblewski\u00a0K, Yap\u00a0BJ et\u00a0al (2015) Grading financial toxicity based upon its impact on health-related quality of life (HRQol). J\u00a0Clin Oncol 33:6618\u20136618. https:\/\/doi.org\/10.1200\/jco.2015.33.15_suppl.6618","journal-title":"J Clin Oncol"},{"key":"2479_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1634\/theoncologist.2012-0279","volume":"18","author":"SY Zafar","year":"2013","unstructured":"Zafar\u00a0SY, Peppercorn\u00a0JM, Schrag\u00a0D et\u00a0al (2013) The Financial Toxicity of Cancer Treatment: A\u00a0Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient\u2019s Experience. The Oncol 18:381\u2013390. https:\/\/doi.org\/10.1634\/theoncologist.2012-0279","journal-title":"The Oncol"},{"key":"2479_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1200\/JCO.2015.62.0468","volume":"34","author":"KR Yabroff","year":"2016","unstructured":"Yabroff\u00a0KR, Dowling\u00a0EC, Guy\u00a0GP et\u00a0al (2016) Financial Hardship Associated With Cancer in the United States: Findings From a\u00a0Population-Based Sample of Adult Cancer Survivors. J\u00a0Clin Oncol 34:259\u2013267. https:\/\/doi.org\/10.1200\/JCO.2015.62.0468","journal-title":"J Clin Oncol"},{"key":"2479_CR18","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1177\/10499091231187999","volume":"41","author":"JP Harris","year":"2024","unstructured":"Harris\u00a0JP, Ku\u00a0E, Harada\u00a0G et\u00a0al (2024) Severity of Financial Toxicity for Patients Receiving Palliative Radiation Therapy. Am J Hosp Palliat Med 41:592\u2013600. https:\/\/doi.org\/10.1177\/10499091231187999","journal-title":"Am J Hosp Palliat Med"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-025-02479-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-025-02479-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-025-02479-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T11:06:22Z","timestamp":1772449582000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-025-02479-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2479"],"URL":"https:\/\/doi.org\/10.1007\/s00066-025-02479-9","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.L.\u00a0Kreuser, S.\u00a0Ziegler, S.\u00a0Bendrich, A.\u00a0Ziegler, T.\u00a0Asendorf, O.\u00a0Rick, L.H.\u00a0Dr\u00f6ge, M.\u00a0Leu, M.\u00a0Guhlich, J.\u00a0Oelmann, L.A.\u00a0Fischer, J.\u00a0Fischer, F.\u00a0Braulke, S.\u00a0Rieken, and R.\u00a0El Shafie declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval\n                      : The study was approved by the University Medical Center G\u00f6ttingen ethical review board, entry number 18\/3\/23.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}